Bluejay Diagnostics Announces 1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
| BJDX Stock | USD 4.22 0.11 2.68% |
Slightly above 55% of Bluejay Diagnostics' investors are presently thinking to get in. The analysis of overall sentiment of trading Bluejay Diagnostics stock suggests that some investors are interested at this time. Bluejay Diagnostics' investing sentiment can be driven by a variety of factors including economic data, Bluejay Diagnostics' earnings reports, geopolitical events, and overall market trends.
Bluejay |
ACTON, Mass., Aug. 25, 2023 Bluejay Diagnostics, Inc. , a medical technology company...
Read at globenewswire.com
 |
Bluejay Diagnostics Fundamental Analysis
We analyze Bluejay Diagnostics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bluejay Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bluejay Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
Bluejay Diagnostics is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Bluejay Diagnostics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bluejay Diagnostics stock to make a market-neutral strategy. Peer analysis of Bluejay Diagnostics could also be used in its relative valuation, which is a method of valuing Bluejay Diagnostics by comparing valuation metrics with similar companies.
Peers
Bluejay Diagnostics Related Equities
| NXL | Nexalin Technology | 10.77 | ||||
| NUWE | Nuwellis | 10.62 | ||||
| BBLG | Bone Biologics | 4.08 | ||||
| IRIX | IRIDEX | 1.86 | ||||
| HSCS | Heart Test | 0.92 | ||||
| TIVC | Tivic Health | 7.69 |
Additional Tools for Bluejay Stock Analysis
When running Bluejay Diagnostics' price analysis, check to measure Bluejay Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluejay Diagnostics is operating at the current time. Most of Bluejay Diagnostics' value examination focuses on studying past and present price action to predict the probability of Bluejay Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluejay Diagnostics' price. Additionally, you may evaluate how the addition of Bluejay Diagnostics to your portfolios can decrease your overall portfolio volatility.